Table 1 Specificity and sensitivity of four methylation scoring methods across individual genes and the combined epiCervix panel.

From: Enhancing the sensitivity of non-invasive cervical cancer detection using CpG methylation haplotype profiling

Gene / Panel

Specificity (Normal, %)

Sensitivity (Cancer, %)

 

fHMH

pHMH

Median

Single CpG

fHMH

pHMH

Median

Single CpG

CA10

97.99

97.99

97.49

98.49

81.65

82.57

76.15

66.06

DPP10

97.49

97.49

97.49

98.49

66.97

60.55

52.29

37.61

FMN2

98.49

97.99

97.99

96.98

70.64

69.72

56.88

50.46

HAS1

98.49

97.99

98.49

97.49

81.65

67.89

62.39

66.06

epiCervix

94.47

93.47

93.97

94.47

89.91

87.16

77.98

71.56

  1. Thresholds were defined at the 99th percentile of the normal distribution for each marker. Specificity represents the percentage of normal samples below this threshold, and sensitivity the percentage of cancer samples above this threshold (108 cancers, 169 normals)
  2. fHMH, full Highly Methylated Haplotype (all CpGs methylated)
  3. pHMH, partial Highly Methylated Haplotype (≥ predefined CpGs methylated)
  4. Median, median methylation across CpGs in the region
  5. Single CpG, specific CpG site (cg20405017 for CA10; cg21678377 for DPP10; cg01650149 for FMN2; cg13944175 for HAS1)
Back to article page